Wedbush Maintains Outperform on ARS Pharmaceuticals, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides has maintained an Outperform rating on ARS Pharmaceuticals (NASDAQ:SPRY) and increased the price target from $5 to $13.
November 13, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides reaffirmed an Outperform rating on ARS Pharmaceuticals and raised the price target to $13, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Andreas Argyrides suggests a strong conviction in the company's future performance. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100